Management strategies for inhibitors include immune tolerance induction (ITI), bypassing agents, and gene therapy. ITI involves the administration of high doses of clotting factor concentrates to train the immune system to tolerate the factor. Bypassing agents, such as recombinant factor VIIa or activated prothrombin complex concentrates, are used to control bleeding when inhibitors are present. Gene therapy is an emerging field showing promise in long-term management of hemophilia.
